Pembrolizumab + Infliximab for Metastatic Melanoma
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this research is to test the safety and effectiveness of the investigational
combination of pembrolizumab and infliximab in treating metastatic melanoma.